Drug General Information
Drug ID
D0Q7JC
Former ID
DIB011227
Drug Name
P-552-02
Synonyms
CF-552; KM-003; P-552; Sodium channel blocker (oral, dry mouth/ Sjogren's syndrome), Parion Sciences
Drug Type
Small molecular drug
Indication Cystic fibrosis [ICD9: 277; ICD10:E84] Phase 1/2 [467618], [523506]
Company
Parion Sciences Inc
Structure
Download
2D MOL

3D MOL

Formula
C19H26ClN7O4
InChI
InChI=1S/C19H26ClN7O4/c20-15-17(22)26-16(21)14(25-15)18(30)27-19(23)24-8-2-1-3-11-4-6-13(7-5-11)31-10-12(29)9-28/h4-7,12,28-29H,1-3,8-10H2,(H4,21,22,26)(H3,23,24,27,30)
InChIKey
NTRKMGDUWYBLMS-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Sodium channel Target Info Blocker [551923]
KEGG Pathway Dopaminergic synapse
Reactome Interaction between L1 and Ankyrins
References
Ref 467618(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4280).
Ref 523506ClinicalTrials.gov (NCT01369589) An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness. U.S. National Institutes of Health.
Ref 551923US patent application no. 2014,0221,286, Sodium channel blockers reduce glucagon secretion.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.